It’s challenging to be heard in the corridors of Parliament, which is why many patient organisations and NFPs engage federal lobbyists. We reveal who uses who.
2 days ago | In Patients, PoliticsIndependent report finds US launch prices rose 35% in four years with two in three prescriptions not being filled, demonstrating US access is not perfect.
2 days ago | In Industry, PatientsForges new strategic partnership to support the potential commercialisation of a topical gel for the treatment of diabetic foot infections.
2 days ago | In Companies, ProductsCSL targeted by a shareholder class action over alleged misleading profit guidance, the case just one issue incoming CEO Deborah Waterhouse will need to manage.
2 days ago | In CompaniesA new report from PatientView examines how Australian patient organisations influence HTA and access and finds them highly engaged.
4 days ago | In ESG, Patients, Reputationargenx global VP Beth DelGiacco tells MedNews why patients, not pricing, guide decisions, and why they haven’t signed an MFN deal.
4 days ago | In Companies, People, ReputationWith no national strategy, Australians are increasingly facing inequitable and tougher access to CAR T cell therapies, a global IQVIA report finds.
4 days ago | In Cell and gene therapies, Patients, ProductsWhat happens when the need is there but the cupboard is bare? Labor’s claim to be the party of Medicare and the PBS is looking shaky as funding dries up.
Victoria “the only place in the world to host both global leaders in mRNA, leading the future of medical innovation”